Justin Woodruff
Family · Brigham City, UTNPI 1063020949
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $24,750 of the $30,249 with a category attached, or 81.8%. AbbVie accounts for 89.4% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2023 at $14,163 and has fallen 69.3% since, to $4,352 in 2025. Among family clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 275 payments — averaging $110.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$27K
- Otsuka America Pharmaceutical, Inc.$747
- Neurocrine Biosciences, Inc.$586
- Vanda Pharmaceuticals Inc.$430
- Alkermes, Inc.$413
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$287
- plus $747 from 10 others
What the payments were for
- Speaking & faculty fees$24,75082%
- Travel & lodging$1,1834%
- Food & beverage$4,31614%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 95 | $27,038 |
| Otsuka America Pharmaceutical, Inc. | 55 | $747 |
| Neurocrine Biosciences, Inc. | 26 | $586 |
| Vanda Pharmaceuticals Inc. | 17 | $430 |
| Alkermes, Inc. | 26 | $413 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $287 |
| Teva Pharmaceuticals USA, Inc. | 16 | $279 |
| Lundbeck LLC | 9 | $156 |
| Indivior Inc. | 6 | $132 |
| Axsome Therapeutics, Inc. | 3 | $59 |
| Johnson & Johnson | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Tris Pharma Inc | 1 | $22 |
| Vertical Pharmaceuticals, LLC | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Noven Therapeutics, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$25,585
How this compares
$30,249 in reported general payments places this provider in the 95th percentile of 1,460 family providers in Utah.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 24 | $180,863 |
| VraylarCariprazine Hcl | 149 | $155,196 |
| Invega SustennaPaliperidone Palmitate | 42 | $117,423 |
| Abilify MaintenaAripiprazole | 33 | $89,316 |
| AristadaAripiprazole Lauroxil | 16 | $50,960 |
| RexultiBrexpiprazole | 43 | $42,923 |
| FanaptIloperidone | 30 | $30,816 |
| BelsomraSuvorexant | 42 | $17,693 |
| Risperdal ConstaRisperidone Microspheres | 12 | $13,187 |
| SpravatoEsketamine Hcl | 17 | $12,881 |
| Lurasidone Hcl | 75 | $8,607 |
| SaphrisAsenapine Maleate | 11 | $6,236 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 31 | $5,131 |
| ViibrydVilazodone Hcl | 11 | $4,592 |
| Duloxetine Hcl | 76 | $2,669 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $586 | $180,86324 claims |
| AbbVieVraylar, Saphris, Viibryd | $27,038 | $166,025171 claims |
| Johnson & JohnsonInvega Sustenna, Risperdal Consta, Spravato | $28 | $143,49171 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $747 | $132,23976 claims |
| Alkermes, Inc.Aristada | $413 | $50,96016 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $430 | $30,81630 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,460 family providers in Utah.
Other family in Brigham City
- Riley WorthSandy$1.1M
- Katrina BawdenSalt Lake City$395K
- Cortnee RomanSalt Lake City$374K
- Jared ThorleySalt Lake City$368K
- Stephanie GodfreyLindon$358K
- Mary SteinbackSalt Lake City$189K
- Shannon FordSouth Jordan$186K
- Jennalyn MayeuxSalt Lake City$151K
- Brett RawlinsKaysville$149K
- Shelby MillerSandy$140K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.